These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
423 related articles for article (PubMed ID: 31181361)
1. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure. Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361 [TBL] [Abstract][Full Text] [Related]
2. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide. Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286 [TBL] [Abstract][Full Text] [Related]
3. Women with prolactinomas presented at the postmenopausal period. Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223 [TBL] [Abstract][Full Text] [Related]
4. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when? Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552 [TBL] [Abstract][Full Text] [Related]
5. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080 [TBL] [Abstract][Full Text] [Related]
6. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion. Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811 [TBL] [Abstract][Full Text] [Related]
8. Prolactinomas: evolution after menopause. Mallea-Gil MS; Manavela M; Alfieri A; Ballarino MC; Chervin A; Danilowicz K; Diez S; Fainstein Day P; García-Basavilbaso N; Glerean M; Guitelman M; Katz D; Loto MG; Martinez M; Miragaya K; Moncet D; Rogozinski AS; Servidio M; Stalldecker G; Vitale M; Boero L Arch Endocrinol Metab; 2016 Feb; 60(1):42-6. PubMed ID: 26909481 [TBL] [Abstract][Full Text] [Related]
9. Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth? Alkabbani AG; Mon SY; Hatipoglu B; Kennedy L; Faiman C; Weil RJ; Hamrahian AH Pituitary; 2014 Apr; 17(2):97-102. PubMed ID: 23468127 [TBL] [Abstract][Full Text] [Related]
10. Falsely low serum prolactin in two cases of invasive macroprolactinoma. Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675 [TBL] [Abstract][Full Text] [Related]
11. Giant prolactinomas in men: efficacy of cabergoline treatment. Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451 [TBL] [Abstract][Full Text] [Related]
12. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists. Burlacu MC; Maiter D; Duprez T; Delgrange E Endocrine; 2019 Feb; 63(2):323-331. PubMed ID: 30267354 [TBL] [Abstract][Full Text] [Related]
13. Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. Santharam S; Fountas A; Tampourlou M; Arlt W; Ayuk J; Gittoes N; Toogood A; Karavitaki N Clin Endocrinol (Oxf); 2018 Sep; 89(3):346-353. PubMed ID: 29894000 [TBL] [Abstract][Full Text] [Related]
14. MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment. Eroukhmanoff J; Tejedor I; Potorac I; Cuny T; Bonneville JF; Dufour H; Weryha G; Beckers A; Touraine P; Brue T; Castinetti F Eur J Endocrinol; 2017 Mar; 176(3):323-328. PubMed ID: 28073906 [TBL] [Abstract][Full Text] [Related]
15. Predictors of dopamine agonist resistance in prolactinoma patients. Vermeulen E; D'Haens J; Stadnik T; Unuane D; Barbe K; Van Velthoven V; Gläsker S BMC Endocr Disord; 2020 May; 20(1):68. PubMed ID: 32429916 [TBL] [Abstract][Full Text] [Related]
16. PRL-R Variants Are Not Only Associated With Prolactinomas But Also With Dopamine Agonist Resistance. de Castro Moreira AR; Trarbach E; Bueno CBF; Monteiro ALS; Grande IPP; Padula M; Maciel GAR; Glezer A J Clin Endocrinol Metab; 2023 Jun; 108(7):e450-e457. PubMed ID: 36638053 [TBL] [Abstract][Full Text] [Related]
17. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas. Iyer P; Molitch ME Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816 [TBL] [Abstract][Full Text] [Related]
18. Diagnosis and drug therapy of prolactinoma. Ciccarelli E; Camanni F Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617 [TBL] [Abstract][Full Text] [Related]
19. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment. Shimon I Arch Med Res; 2023 Dec; 54(8):102883. PubMed ID: 37689507 [TBL] [Abstract][Full Text] [Related]
20. Primary medical therapy of micro- and macroprolactinomas in men. Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]